Published in Sci Rep on November 04, 2015
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev (2004) 9.28
Doxorubicin-induced cardiomyopathy. N Engl J Med (1998) 9.08
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev (2003) 3.69
Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm (2008) 2.94
The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials (2011) 2.45
Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer (2004) 2.31
Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm (2006) 2.28
Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem (2004) 2.21
Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res (1995) 2.18
Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene (2006) 1.83
Subcellular localization and activity of multidrug resistance proteins. Mol Biol Cell (2003) 1.77
Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev (2001) 1.77
Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol (2006) 1.71
Mitochondriotoxic compounds for cancer therapy. Oncogene (2006) 1.31
Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci (2005) 1.20
Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small (2012) 1.20
Multidrug resistance: Physiological principles and nanomedical solutions. Adv Drug Deliv Rev (2013) 1.15
pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv (2013) 1.13
Mitochondria as subcellular targets for clinically useful anthracyclines. Adv Drug Deliv Rev (2001) 1.11
pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery. Biomaterials (2012) 1.08
Mitochondrial reticulum network dynamics in relation to oxidative stress, redox regulation, and hypoxia. Int J Biochem Cell Biol (2009) 1.03
Targeting mitochondria for cancer therapy. Environ Mol Mutagen (2010) 1.03
The expression and functional characterization of sigma (sigma) 1 receptors in breast cancer cell lines. Cancer Lett (2006) 1.02
Thermodynamic and kinetic stability of DSPE-PEG(2000) micelles in the presence of bovine serum albumin. J Phys Chem B (2010) 1.01
Self-assembled polyethylenimine-graft-poly(epsilon-caprolactone) micelles as potential dual carriers of genes and anticancer drugs. Biomaterials (2007) 1.00
Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Mol Pharm (2012) 1.00
Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv Drug Deliv Rev (2008) 0.99
Organelle targeting: third level of drug targeting. Drug Des Devel Ther (2013) 0.97
Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int J Pharm (2009) 0.96
Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients. Int J Cancer (2011) 0.96
The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials (2013) 0.95
Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals. Mol Pharm (2014) 0.94
DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J Control Release (2003) 0.94
P-glycoprotein subcellular localization and cell morphotype in MDR1 gene-transfected human osteosarcoma cells. Biol Cell (1999) 0.91
DQAsomes: a novel potential drug and gene delivery system made from Dequalinium. Pharm Res (1998) 0.89
Mitochondrial targeting drug lonidamine triggered apoptosis in doxorubicin-resistant HepG2 cells. Life Sci (2002) 0.88
DQAsome/DNA complexes release DNA upon contact with isolated mouse liver mitochondria. J Control Release (2001) 0.88
Sigma receptors and their ligands in cancer biology: overview and new perspectives for cancer therapy. Med Res Rev (2010) 0.88
Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. Mol Oncol (2014) 0.87
Dual drug conjugated nanoparticle for simultaneous targeting of mitochondria and nucleus in cancer cells. ACS Appl Mater Interfaces (2015) 0.86
Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin. Biomaterials (2014) 0.86
Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy. Acta Biomater (2013) 0.86
Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo. Int J Cancer (1997) 0.83
Mitochondrial delivery of doxorubicin via triphenylphosphine modification for overcoming drug resistance in MDA-MB-435/DOX cells. Mol Pharm (2014) 0.83
Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle. Int J Pharm (2011) 0.82
Intracellular pH-sensitive PEG-block-acetalated-dextrans as efficient drug delivery platforms. ACS Appl Mater Interfaces (2013) 0.82
pH-sensitive liposomes for drug delivery in cancer treatment. Ther Deliv (2013) 0.81
Cellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticles. PLoS One (2014) 0.81
Bioreducible core-crosslinked hyaluronic acid micelle for targeted cancer therapy. J Control Release (2014) 0.80
Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles. Biomaterials (2014) 0.80
Doxorubicin loaded pH-responsive micelles capable of rapid intracellular drug release for potential tumor therapy. J Biomed Nanotechnol (2014) 0.79
Design and synthesis of a mitochondria-targeting carrier for small molecule drugs. Org Biomol Chem (2014) 0.79
A differential interaction of daunomycin, adriamycin and their derivatives with human erythrocytes and phospholipid bilayers. Biochim Biophys Acta (1978) 0.79
Repression of phosphoinositide-dependent protein kinase 1 expression by ciglitazone via Egr-1 represents a new approach for inhibition of lung cancer cell growth. Mol Cancer (2014) 0.79
Anisamide-Decorated pH-Sensitive Degradable Chimaeric Polymersomes Mediate Potent and Targeted Protein Delivery to Lung Cancer Cells. Biomacromolecules (2015) 0.78
Failure to enhance the in vivo killing of human ovarian carcinoma by sequential treatment with dequalinium chloride and tumor necrosis factor. Gynecol Oncol (1993) 0.78
Development of synthetic of peptide-functionalized liposome for enhanced targeted ovarian carcinoma therapy. Int J Clin Exp Pathol (2015) 0.77
Active Drug Targeting of a Folate-Based Cyclodextrin-Doxorubicin Conjugate and the Cytotoxic Effect on Drug-Resistant Mammary Tumor Cells In Vitro. J Pharm Sci (2015) 0.76
Development and characterization of lyophilized diazepam-loaded polymeric micelles. AAPS PharmSciTech (2013) 0.76
Editorial: Mitochondria and subcellular organelles as treatment targets against pathological conditions. Curr Pharm Des (2014) 0.76
Site specific/targeted delivery of gemcitabine through anisamide anchored chitosan/poly ethylene glycol nanoparticles: an improved understanding of lung cancer therapeutic intervention. Eur J Pharm Sci (2012) 0.76
PEG-detachable lipid-polymer hybrid nanoparticle for delivery of chemotherapy drugs to cancer cells. Anticancer Drugs (2014) 0.76
Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer. Sci Rep (2015) 0.78
Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance. Sci Rep (2016) 0.75
Development, Optimization, and Characterization of PEGylated Nanoemulsion of Prostaglandin E1 for Long Circulation. AAPS PharmSciTech (2015) 0.75
Charge reversible calcium phosphate lipid hybridnanoparticle for siRNA delivery. Oncotarget (2017) 0.75